Joshua A. Korsen

Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM

Jason S. Lewis, N. Cheung, A. Piersigilli, 2021, The Journal of Nuclear Medicine.

ImmunoPET Imaging of Pancreatic Tumors with 89Zr-Labeled Gold Nanoparticle–Antibody Conjugates

Jason S. Lewis, Joshua A. Korsen, K. J. Edwards, 2020, Molecular Imaging and Biology.

Antibody-Based Molecular Imaging

Jason S. Lewis, V. Nagle, Joshua A. Korsen, 2021, Molecular Imaging.

Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3

C. Rudin, M. Morris, Jason S. Lewis, 2022, The Journal of Nuclear Medicine.

Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer

C. Rudin, M. Morris, Jason S. Lewis, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Synthetic molecular recognition nanosensor paint for microalbuminuria

Prakrit V. Jena, Thomas V. Galassi, Jackson D. Harvey, 2019, Nature Communications.

Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer

Henry W. Long, O. Elemento, H. Beltran, 2023, Nature Cancer.

Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET

C. Rudin, Jason S. Lewis, V. Sisodiya, 2021, Bioconjugate chemistry.

Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity.

C. Rudin, W. Travis, Jason S. Lewis, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.

Subhiksha Nandakumar, Joshua A. Korsen, Cinzia Imberti, 2024, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.